Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other neoplasm 1Other hematologic neoplasm 1

Conditions

Precancerous Conditions 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1

Interventions

Sulindac 4Biopsy 4Carboplatin 3Vaginal Smears 2Specimen Handling 2Cyclophosphamide 2Colposcopy 2Aspirin 2tipifarnib 1tanespimycin 1sargramostim 1radium Ra 223 dichloride 1pirfenidone 1fludarabine phosphate 1alethine 1X-Rays 1Taxes 1Sorafenib 1Resistance Training 1Radiotherapy 1Polymerase Chain Reaction 1Photons 1Peripheral Blood Stem Cell Transplantation 1Papanicolaou Test 1Paclitaxel 1Mycophenolic Acid 1Microarray Analysis 1Magnetic Resonance Spectroscopy 1Lovastatin 1Interleukin-12 Subunit p35 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × alethine × Other neoplasm × Clear all
NCT00006466 2013-12-18

Beta Alethine in Treating Patients With Myeloma

National Cancer Institute (NCI)

Phase 1/2 Unknown
Other neoplasmPlasma cell

Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Precancerous Conditions, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡